November 4, 2025 — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) has completed enrollment in extension cohort 4 of its soquelitinib atopic dermatitis Phase 1 trial, with data expected in January. The company is also on track to initiate its Phase 2 atopic dermatitis trial in early Q1 2026.
Additionally, the Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) is enrolling, and final Phase 1/1b results have been accepted for oral presentation at the American Society of Hematology Annual Meeting.
Corvus will host a conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update and discuss the third quarter 2025 financial results.
As of September 30, 2025, Corvus had cash, cash equivalents, and marketable securities of $65.7 million, which is expected to fund operations into the fourth quarter of 2026.
Key developments include:
- Completion of enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4.
- Phase 2 trial initiation for soquelitinib in atopic dermatitis is on track for early Q1 2026.
- Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) is enrolling, with multiple clinical sites open.
- Final Phase 1/1b results accepted for oral presentation at the American Society of Hematology Annual Meeting.
Investor Contact: Leiv Lea, Chief Financial Officer, Corvus Pharmaceuticals, Inc., +1-650-900-4522, llea@corvuspharma.com
Media Contact: Sheryl Seapy, Real Chemistry, +1-949-903-4750, sseapy@realchemistry.com
Source: Corvus Pharmaceuticals
